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Abstract
We evaluated intratumor (IT) versus intravenous (IV) administration of the photosensitizer Pc 4 with respect to tu-
mor photosensitizer concentration, specificity, and responses to irradiation. BALB/c mice bearing intradermal
EMT6 tumors were given 0.3 mg/kg Pc 4 injected IT or IV through the tail vein. Photosensitizer concentration
was evaluated by chloroform extraction and localization assessed by fluorescence imaging and spectroscopy
in vivo. Tumors were irradiated at 667 nm, 50 mW/cm2, and 100 J/cm2. Cures were defined as no palpable tumor
90 days after irradiation. Tumor Pc 4 concentrations 1 hour after IT administration were 35,000-fold higher than
measured 24 hours after IV administration (0.112 vs 0.317 × 10−5 μg Pc 4/mg tumor). Exquisite tumor selectivity
was observed 1 hour after IT injection. Fluorescence imaging of freshly sectioned tumors revealed no regions de-
void of sensitizer at this time point, with pixel intensities in a midline section within a factor of 3 of the peak in-
tensity. For identical photosensitizer doses, IT administration significantly improved tumor responses to irradiation,
with more than 70% of tumors cured with IT–Pc 4–PDT. In this model, IT–Pc 4 administration provides improved
tumor control, greater selectivity, and opportunity for a short drug-light interval.
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Introduction
Intravenous (IV) and topical routes of photosensitizer administration
are widely used in clinical and preclinical applications of photo-
dynamic therapy (PDT). Topical application of various formulations
of the prodrug aminolevulinic acid (ALA) is routinely performed for
superficial lesions in the skin [1]. ALA has also been administered
orally for PDT of tumors not accessible to topical delivery [2,3]
and for fluorescence-guided surgical tumor resection [4].
Direct intratumor (IT) delivery of photosensitizers has been inves-
tigated only sporadically, and the previous literature on this subject is
relatively sparse and conflicted. Kostron et al. [5] compared intraperi-
toneal (IP) and IT injection of hematoporphyrin derivative (HPD) in
subcutaneous and in intracerebral gliosarcomas in a rat model. They
reported three- to four-fold increases in tritiated HPD at both tumor
sites after IT versus IP administration. Selectivity was also enhanced
significantly. The increased HPD concentrations in tumors after di-
rect IT injection resulted in improved photodynamic inactivation of
the tumor cells, as measured using in vivo and in vitro clonogenic
assays. In a pair of articles published in 1988, Amano et al. [6]
and Lin et al. [7] also reported results of experiments designed to
evaluate IT delivery of HPD. Motivated primarily by the persistent
skin photosensitivity that results from systemic administration of
HPD and a number of other photosensitizers, these authors dem-
onstrated HPD concentrations in a subcutaneous mouse bladder tu-
mor line 3 to 15 times higher with IT relative to IP injection [6].
Increased tumor HPD concentrations did not, however, result in im-
proved tumor cell killing under the conditions of this study [7],
which was attributed to a possible lack of efficient tumor blood vessel
photosensitization with IT administration. Gibson et al. [8] investi-
gated IT delivery of Photofrin II in a transplanted subcutaneous rat
mammary tumor. Photosensitizer levels were not measured directly.
Using an in vivo – in vitro protocol, in which Photofrin was injected
in vivo through an IT or IP route and tumor and liver mitochondria
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preparations were subsequently irradiated in vitro, activities of two
mitochondrial enzymes were attenuated to a significantly greater de-
gree when irradiation of tumor samples was performed 2 hours after
IT injection. Irradiation of tumor and liver mitochondrial preparations
at 2 hours after IT Photofrin injection showed tumor selectivity, with
activities of enzymes in liver mitochondria 5- to 10-fold less susceptible
to PDT-mediated damage. This study also showed increased efficacy of
Photofrin PDT as measured by tumor growth delay when irradiation
was performed 2 hours after Photofrin injection IT versus IP.
IT delivery of the photosensitizer methylene blue has received
slightly more attention in the literature, in part because it is reduced
to a colorless, photodynamically inactive form when injected system-
ically [9]. König et al. [10] showed significant reduction in tumor
mass in small subcutaneous Ehrlich carcinomas in mice in response
to methylene blue administered through several IT injections and
multiple laser irradiations delivered in daily fractions. Two articles
by Orth et al. [11,12] described the efficacy of IT–methylene
blue–PDT in colorectal tumors in mice. Their latter article reported
no evidence of tumor in 79% of mice 5 weeks after an initial PDT
treatment, with a second methylene blue injection and irradiation
performed at 2 weeks if the tumor had not been eradicated by the
first treatment. Encouraging results were reported from a small pilot
study in three esophageal cancer patients [13]. Methylene blue was
injected directly into inoperable, recurrent carcinomas under endo-
scopic guidance, and laser irradiation was performed 1 hour later.
After two treatments within a 2-week period, there were no adverse
side effects and no macroscopic evidence of tumor.
Very recently, two reports have evaluated ITmeso-tetrahydroxyphenyl
chlorin (mTHPC, Foscan) administration in rodent models of breast
[14] and brain [15] cancer. Both studies were motivated by the pro-
longed skin photosensitivity associated with this promising photosen-
sitizer. D’Hallewin et al. [14] used the liposomal formulation, Foslip,
and showed maximum IT mTHPC fluorescence and irradiation-
induced tumor necrosis at a 24-hour drug-light interval. This surpris-
ingly long optimal interval was attributed to concentration quenching
within liposomes and a relatively long rate of redistribution, thus
drawing attention to the importance of the sensitizer formulation.
In an intracranial glioma model in rats, Mannino et al. [15] found
comparable tumor uptake and tumor-to-normal tissue ratios after IP
and IT Foscan delivery in an ethanol/ethylene glycol (40:60) vehicle
but found that favorable results were obtained in the IT case with
20-fold lower administered photosensitizer dose and a shorter
(4 hours) drug-light interval.
Despite some promising initial studies, IT photosensitizer adminis-
tration has not been pursued systematically and it remains an under-
studied area with significant clinical potential. The purpose of our
study was to perform the first investigation of the IT delivery of
the second-generation photosensitizer Pc 4, a topical formulation
of which has been evaluated in a phase 1 clinical trial for the treatment
of cutaneous T-cell lymphoma [16]. Here we describe extremely high
sensitizer concentrations, excellent tumor selectivity, and long-term
cures using IT–Pc 4–PDTwith a short 1-hour drug-light interval.
Materials and Methods
Animal and Tumor Model
Mouse mammary EMT6 tumors were initiated on the backs of
female BALB/c mice by the intradermal (ID) injection of 106 cells.
Animals were followed daily to track tumor growth and were fed ex-
clusively on a chlorophyll-free diet prepared according to the recipe
of Holmes et al. [17] to eliminate chlorophyll-derived fluorescence.
Approximately 7 to 10 days after implantation when the tumors
reached a volume of approximately 25 to 40 mm3, they were used
for control, PDT treatment, or drug extraction studies. For in vivo
imaging of host cell infiltration and perfusion, tumors were initiated
by the injection of 5 × 105 EMT6 cells into the ID space of the ear
pinna [18].
Photosensitizer Administration and Light Treatment
The silicon phthalocyanine photosensitizer, Pc 4 [16], was prepared
as described previously [19]. Pc 4 was dissolved in a 50% ethanol–
50% Cremophor solution, and a stock concentration of 2.1 mg/ml
was prepared. The stock was diluted in a ratio of 1:9 in 0.9% saline
to a final concentration of 0.21 mg/ml. The volume for IT injection
was approximately 35 μl, which was injected at a single point near
the center of the tumor using a 29-gauge needle. For IV injection,
35 μl of 0.21 mg/ml was further diluted in 65 μl of 90% saline,
5% ethanol, and 5% Cremophor. To facilitate direct comparison, the
dose of administered Pc 4 through either IT or IV route was main-
tained at 0.3 mg/kg. After 1 hour and 24 hours of drug-light inter-
vals for IT and IV administration, respectively, the tumors were
subjected to PDT irradiation using 667-nm light from a diode laser
(Power Technology, Inc, Little Rock, AR). Light was delivered
through a GRIN-lens-terminated multimode fiber (OZ Optics,
Ottawa, Ontario, Canada), and the tumors were illuminated with
a fluence of 100 J/cm2 at an irradiance of 50 mW/cm2. Controls
included untreated ((−) drug, (−) light) animals and mice receiving
only 0.3 mg/kg Pc 4 IT (no light).
Drug Extraction
Pc 4 levels in the tumor after IV and IT injection were quantified
using chloroform extraction. To accomplish this, 0.3 mg/kg Pc 4 was
injected either IT or IV. Either 1 hour (IT) or 24 hours (IV) after
injection, the mouse was euthanized and the tumor was excised.
For mice that received IT injection, the skin immediately adjacent
to the tumor was also harvested. Tumors were weighed and subjected
to chloroform extraction (D. Kessel, personal communication). First,
tumors were homogenized in a tissue grinder containing 1 ml of
Hank’s balanced salt solution per 10 mg of tumor. The amount
0.8 ml of MeOH per 10 mg of tumor was added to the solution
and vortexed; next, 0.8 ml of chloroform per 10 mg of tumor was
added. The solution was then centrifuged at 227g for 10 minutes
to allow for the separation of the aqueous and chloroform phases.
The bottom layer consisting of the chloroform and the solubilized
drug was transferred to a cuvette, and absorbance and fluorescence
measurements were performed for IT and IV administration, respec-
tively. The Pc 4 concentration was calculated from these measurements
using a calibration curve generated from the absorbance and fluores-
cence peak amplitudes of known Pc 4 concentrations in the same sol-
vent. Skin sections were frozen in liquid nitrogen for 30 minutes and
powdered with a frozen pestle before homogenization. Otherwise, they
were treated identically to tumor sections.
Photosensitizer Fluorescence Imaging and Spectroscopy
Photosensitizer distribution and degree of tumor localization were
assessed through in vivo imaging. One hour after IT–Pc 4 injection,
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anesthetized mice were positioned on the stage of a stereofluorescence
microscope (Model SMZ1500; Nikon Instruments, Melville, NY)
equipped with an Xcite illumination source (EXFO, Ontario, Canada)
and a computer-controlled x-y translation stage (H101A ProScanII;
Prior Scientific, Rockland, MA). Excitation of Pc 4 and fluorescence
collection were accomplished using a custom filter cube (HQ560/120x;
635DCXR;HQ645LPm,ChromaTechnology, Rockingham,VT). In-
dividual fields acquired using a 0.5× objective with a 0.75× magnifica-
tion zoom corresponded to fields of view (FOVs) of 25.2mm × 19mm.
Images of entire mice were constructed by translating the stage and
stitching individual fields to create a montage (MetaVue 6.1; Molecular
Devices, Sunnyvale, CA).
To examine the detailed spatial distribution of Pc 4 in the tumors
and immediately adjacent normal skin, 1 hour after injection, mice
were euthanized and tumors were excised immediately. Tumors were
sectioned mediolaterally, and the resulting fresh section was imaged
with the stereofluorescence microscope (0.5× objective, 2× zoom).
Skin was left on the excised tumor tissue to provide spatial orientation.
High-resolution images of 1390 × 1040 pixels with an FOVof 9.5mm×
7 mm were captured and digitized by a Photometrics 12-bit mono-
chrome CCD camera (CoolSNAPHQ; Roper Scientific, Inc, Trenton,
NJ). To assess sensitizer heterogeneity, image analysis was performed on
the tumor region using the Surface Plot tool in ImageJ (NIH; URL:
http://rsb.info.nih.gov/ij/).
In vivo fluorescence spectroscopy measurements were made using a
system and custom multiple-optical-fiber probe described previously
[20]. Briefly, Pc 4 fluorescence was excited using a 639-nm laser
(Power Technology), and broadband reflectance was acquired using
a white light source (75-W xenon arc lamp, model 6263; Oriel In-
struments, Stratford, CT). Light from these sources and the fluores-
cence and reflectance signals were transmitted to/from the tissue
surface through dedicated fibers in the probe. Signals were imaged
onto a TE-cooled, 16-bit, 512 × 512 pixel CCD camera (Pixis512;
Princeton Instruments, Princeton, NJ) through an imaging spectro-
graph (SpectraPro 275; Acton Research Corp, Acton, MA). A long-pass
filter (650AELP; Omega Optical, Brattleboro, VT) in the detection
path was positioned to reject excitation light. The signal measured by
the CCD was first corrected for instrument response.
To minimize the possibly confounding effects of tissue optical
properties on the measured fluorescence, the fluorescence spectrum
was divided by the reflectance measured in the same wavelength in-
terval and source-detector geometry. Measurements were obtained at
several locations on the tumor as well at both legs. Before measure-
ment, the tumor site and leg areas were shaved, and hair was removed
using a commercial depilating agent (Nair; Church & Dwight, Co,
Princeton, NJ).
Tumor Response Assay and Statistics
After PDT, tumor dimensions along three orthogonal axes were
measured daily using digital calipers. Volumes were computed assum-
ing an approximately ellipsoidal shape with the expression, V = (4/
3)πr1r2r3. Mice were removed from the study if the volume of the
tumor reached twice the pretreatment volume. Cures were defined
as no evidence of palpable tumor 90 days after PDT. Statistical anal-
ysis was performed using pairwise comparisons of tumor regrowth
curves among control, Pc 4–only, IV–PDT, and IT–PDT treatment
groups. A log-rank test was applied to each pair using SAS 9.1 (SAS
Institute, Inc, Cary, NC). Bonferroni adjustments were applied to
the raw P values of the log-rank tests to guard against type I error.
Host Response and Vascular Perfusion Imaging After PDT
In vivo confocal imaging of host responses or perfusion status in
tumors of live mice was performed using a custom laser scanning fluo-
rescence confocal microscope as described previously [21]. Briefly,
anesthetized mice were placed in a supine position with the ear tumors
facing the top of a coverslip mounted on the stage of the inverted mi-
croscope. The fluorophore Alexa Fluor 647 was excited with a 639-nm
diode laser and detected using a 647-nm long-pass filter (Semrock,
Rochester, NY). Alexa Fluor 488 and fluorescein isothiocyanate (FITC)
were excited at 488 nm from an argon ion laser and detected using
a combination of 500-nm long-pass and 515/30 nm band-pass filters
(Chroma Technology). The combination of a 100-μm-diameter pin-
hole and a 10×, 0.45 NA objective gave a 6-μm optical section thick-
ness, and the images were acquired at 16 bits with a lateral resolution
of 1 μm per pixel.
For immunofluorescence imaging in vivo [18,22], antibodies were
purchased directly as fluorescent conjugates. We labeled neutrophil in-
filtration into tumors using ID administration of antimouse GR-1
antibodies (clone RB6-8C5; Biolegend, San Diego, CA). The vessels
in the tumor were labeled by ID injection of antimouse CD31 anti-
bodies (clone MEC13.3; Biolegend). The ID injection volumes of anti-
bodies were approximately 30 μl and concentrations were 0.1 mg/ml.
Antibodies were administered as a cocktail 3 hours before imaging to
allow for clearance of unbound label. To visualize perfusion status in
tumors, 200 μl of 5 mg/ml FITC-dextran (FD2000S; Sigma-Aldrich,
St Louis, MO) was injected IV through the tail vein. Perfusion in
CD31-positive Alexa Fluor 647–labeled tumor vasculature was imaged
as early as 5 minutes after injection.
Results and Discussion
Preliminary imaging of Pc 4 fluorescence in vivo indicated that Pc 4
was distributed throughout the tumor within less than 1 hour after
IT injection. Published studies of Pc 4–PDT in mice typically used a
24-hour drug-light interval with IV administration of 0.6 mg/kg [23].
Thus, our comparisons were made on the basis of these two intervals.
Anticipating favorable Pc 4 concentrations with IT injection, we chose
to compare IT versus IV routes of administration using a two-fold
lower concentration of 0.3 mg/kg. Pc 4 levels in freshly excised tumors
were evaluated using chloroform extraction 1 or 24 hours after IT or
IV administration, respectively. As shown in Table 1, the mean Pc 4
concentration recovered from the tumor 1 hour after IT injection was
approximately 35,000-fold greater than that extracted 24 hours after
IV injection of the same Pc 4 concentration. Because IT administra-
tion resulted in some accumulation in the skin immediately adjacent to
the ID tumor, we measured Pc 4 concentration there as well. Greater
than 95% of the injected Pc 4 was recovered from tumor and imme-
diately adjacent skin, with approximately 65.7% of the injected sensi-
tizer extracted from the tumor and 32.0% from the skin.
In vivo, whole-mouse fluorescence imaging showed a high degree
of localization of Pc 4 in tumors and overlying skin within 1 hour of
Table 1.Mean (±SD) Pc 4 Concentration in Tumors at 1 and 24 Hours after
IT and IV Administration, Respectively, as Quantified by Chloroform
Extraction.
IT – 1 hour (n = 8) IV – 24 hours (n = 6)
0.112 (±0.025) 0.317 × 10
−5 (±0.707 × 10−6)
Concentrations are expressed as micrograms of Pc 4 per milligram of tumor.
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IT injection at a single point (Figure 1). Image analysis revealed fluo-
rescence counts from the normal skin adjacent to the tumor that were
at or very near control levels at this time point. Optical-fiber–based
point fluorescence spectroscopy is more sensitive than imaging to low
fluorophore levels. Thus, we used this technique to evaluate the sys-
temic distribution of Pc 4 to a site remote from the tumor, the leg of
the mouse. At 1 hour after IT injection, singular-value decomposi-
tion analysis [20] of spectra like those shown in Figure 2A indicated
approximately 50-fold greater Pc 4 fluorescence intensity at the tumor
relative to the leg. Spectroscopy measurements performed in mice
24 hours after IV administration showed comparable, low fluorescence
emission from the tumor and the remote site, reflecting little if any
tumor selectivity (not shown). Pc 4 undergoes modest irradiation-
induced photobleaching in human cutaneous T-cell lymphoma le-
sions [24]. We observed photobleaching in the ID murine tumors
as well as shown in Figure 2B. Remarkably, spectroscopy at the tumor
site 24 hours after irradiation showed complete recovery of the Pc 4
fluorescence (Figure 2B). Because there is no evidence that the photo-
bleaching of Pc 4 is reversible, we attribute this increase in fluorescence
to the monomerization of initially aggregated, concentration-quenched
sensitizer, a phenomenon we have observed previously in monolayer
cell culture [25]. Photobleaching followed by more modest increases
in Pc 4 absorption 4 hours after irradiation of tumors sensitized with
2 mg/kg Pc 4 IV was reported recently by Bai et al. [26].
A concern with IT sensitizer delivery is the possibility of extremely
heterogeneous IT distribution. To address this concern directly, we
evaluated Pc 4 fluorescence distribution 1 hour after IT injection
in freshly excised tumor sections using stereofluorescence micros-
copy. As illustrated in the representative image of Figure 3A, no gra-
dient relative to the point of injection was observed. An analysis of
image pixel intensities shown in Figure 3B revealed an approximately
three-fold differential between the maximum and minimum fluores-
cence counts, with fluorescence in all pixels significantly above con-
trol levels. Interestingly, although chloroform extraction revealed a
two-fold greater Pc 4 concentration in the tumor relative to the im-
mediately adjacent skin, this is not reflected in the fluorescence re-
corded in the freshly excised sections. This again is consistent with
significant concentration quenching in the tumor, as noted above.
Tumor growth control was used to compare the therapeutic effi-
cacy of IT versus IV–Pc 4 administration with an irradiation regimen
consisting of 100 J/cm2 delivered at an irradiance of 50 mW/cm2.
The Kaplan-Meier curves of Figure 4 demonstrate that the tumor re-
sponse to Pc 4–PDTand ITadministration was dramatically enhanced
relative to that observed with IV injection of the same photosensitizer
concentration. Among the 15 mice treated with IT administration,
11 (73%) were cured as defined by no evidence of tumor 90 days after
irradiation. No cures were observed in the IV group (n = 8), where the
median tumor volume doubling time was 6 days. The difference in
tumor control between IV– and IT–PDTwas highly significant, with
a Bonferroni-adjusted P < .001. Untreated controls ((−) light, (−) drug)
displayed a median tumor doubling time of 4 days (n = 6), whereas
mice that received Pc 4 injections IT but were not irradiated ((−) light,
(+) drug) showed a modest but statistically significant growth delay
of 10 days (P = .02, n = 5). Tumor regrowth in response to IV–Pc
4–PDT was statistically indistinguishable from that in response to
IT–Pc 4 injection without irradiation (P = 1.0).
Figure 1. Fluorescence image illustrating Pc 4 localization in an ID
tumor 1 hour after IT injection at a single location. The whole mouse
image was created from a series of adjacent stereofluorescence
images, each with 25.2 mm× 19mm FOVs, which were montaged
after acquisition as described in Materials and Methods. Because of
the intense, highly localized fluorescence at the tumor site, the dis-
play is saturated at the tumor to render the rest of the mouse vis-
ible. The inset shows the individual field containing the tumor. Here
the display has been rescaled to eliminate saturation. The bright
central region corresponds to the tumor.
Figure 2. (A) Representative fluorescence spectra obtained from
tumor and remote leg in vivo 1 hour after IT–Pc 4 administration.
(B) Fluorescence spectra from the tumor site before, immediately
after, and 24 hours after irradiation (100 J/cm2), as indicated in the
legend. In all cases, spectra were acquired with 639 nm excitation,
and the fluorescence amplitudes correspond to an acquisition
time of 0.1 second.
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As noted above, Pc 4 was found in the skin immediately adjacent
to the ID tumor. PDTresulted in eschar formation directly above the
tumor, as shown in Figure 5. The skin healed well with complete
regrowth of hair within approximately 3 weeks after irradiation.
When photosensitizers are administered IV, PDT induces a local
inflammatory response that is characterized by leukocyte infiltration,
with a significant fraction of these infiltrating cells being neutrophils
[27–29]. To examine the extent of this response to IT–Pc 4–PDT, we
imaged the influx of GR-1+ neutrophils in tumors in vivo 24 hours
after irradiation. Figure 6, A and B, illustrates the fluorophore-labeled
infiltrating neutrophils imaged in an untreated control and PDT-
treated tumor, respectively. Irradiation resulted in a significant three-
to five-fold (n = 4) enhanced accumulation of GR-1+ cells at this time
point. To the best of our knowledge, these results represent the first
demonstration of a PDT-induced inflammatory response visualized di-
rectly in vivo through noninvasive optical imaging, and they represent
the first characterization of any kind of an acute inflammatory re-
sponse to Pc 4–PDT.
Perfused tumor blood vessels are required for the survival and re-
growth of clusters of PDT-treated tumor cells that escape immediate
phototoxicity, but they may also have an important function in facil-
itating the trafficking of host cells into and out of the treated tumor.
This complex scenario serves to illustrate the importance of the perfu-
sion status of vessels and its role in influencing mechanisms of long-
term tumor response.With this motivation, we imaged tumor perfusion
in live mice before and 24 and 48 hours after IT–Pc 4–PDT using
IV-injected FITC-conjugated high–molecular weight dextran as an
optical perfusion marker [30]. As illustrated in the representative images
of Figure 6, C and D, there was no detectable difference in perfusion
status between the control and treated tumors, thus suggesting that
IT–Pc 4–PDT does not initiate functional damage to the vascula-
ture, at least up to 48 hours after irradiation.
Figure 3. (A) Stereofluorescence image of Pc 4 distribution in a
fresh, excised tumor section. The tumor was excised 1 hour after
IT injection of 0.3 mg/kg Pc 4. The white circle bounds the ID tu-
mor, and the bright regions outside of the circle correspond to the
skin adjacent to the tumor, where Pc 4 concentrations were half
that within the tumor. (B) A surface plot of pixel intensities from
the tumor region of A. The Pc 4 fluorescence counts within the
tumor ranged from approximately 300 to 1000.
Figure 4. Kaplan-Meier curves of tumor responses to IT–Pc 4–PDT.
Laser irradiation at 667 nm was performed at an irradiance of
50 mW/cm2 for a fluence of 100 J/cm2 1 or 24 hours after IT or
IV administration of 0.3 mg/kg Pc 4. Improved efficacy of IT– versus
IV–Pc 4 was highly statistically significant (P < .001).
Figure 5. Digital photographs of the treatment site and surrounding tissue before and at various times after IT–Pc 4–PDT.
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The recent study published by Bai et al. [26] offers interesting
points of comparison with our findings. Using a Pc 4 dose of 2 mg/kg
administered IV and assessing tumor and skin sensitizer concentra-
tions with a form of absorption spectroscopy in vivo, those authors
demonstrated a relationship between tumor Pc 4 levels at the time
of irradiation and tumor response. Their two cures (among 16 PDT-
treated mice) after irradiation with 150 J/cm2 occurred in animals with
the highest Pc 4 concentrations, and among the 14 mice whose tumors
regrew, a correlation between tumor growth delay and IT–Pc 4 con-
centration was demonstrated. Thus, these data suggest that photosen-
sitizer concentration can be a limiting factor in tumor response to PDT
in vivo. Of course, it is not possible to arbitrarily increase the amount
of systemically administered drug, which makes IT delivery very attrac-
tive in those situations where it is clinically feasible. Indeed, it is un-
likely that the extremely high IT–Pc 4 concentrations realized in our
experiments could ever be achieved with systemic administration, even
if toxicity and skin photosensitivity were of no concern.
In addition to greatly increased sensitizer concentrations in the tar-
get tissue, IT administration of Pc 4 offers exceptional selectivity. As
observed also by Bai et al. [26], we found no tumor selectivity up to
24 hours after IV Pc 4 delivery. Peak selectivity at 48 hours was a
modest 2.1-fold, whereas spectroscopy in our study revealed at least
50-fold tumor-to-normal skin selectivity in as little as 1 hour after IT
administration. The ability to achieve high selectivity at very short
drug-light intervals would be attractive to patients and clinicians, en-
abling an entire treatment to be completed within a single, reason-
ably short visit. Yet another potential advantage of IT administration
is the opportunity it presents for using less drug per patient, thereby
lowering the cost of PDT substantially. Finally, taken together, re-
duced persistent skin photosensitivity, good IT distribution, and
lower cost would facilitate repeat PDT treatments, which would be
more difficult for those photosensitizers that are retained in the skin.
Beyond those tumor sites that are obviously accessible to IT injec-
tion, the capabilities of modern interventional radiology render many
solid tumors throughout the body candidates for this approach.
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Figure 6. (A, B) In vivo confocal images of Alexa Fluor 488–conjugated anti–GR-1+ neutrophils (green) and Alexa Fluor 647–conjugated
anti-CD31 vessels (red) in EMT6 tumors grown in the ears of a BALB/c mouse. (A) Control untreated tumor and (B) IT–Pc 4–PDT–treated
tumor 24 hours after irradiation. GR-1+ neutrophils and CD31+ vessels were imaged by ID injection of approximately 30 μl of 0.1 mg/ml
fluorophore-conjugated antibodies into the ear 3 hours before imaging. (C, D) In vivo confocal fluorescence images of perfusion (green)
in CD31-positive vessels (red) in (C) control untreated EMT6 ear tumors and (D) IT–Pc 4–PDT–treated tumor 48 hours after irradiation.
Perfusion was imaged by injecting 200 μl of 5 mg/ml FITC–dextran IV through the tail vein, and the perfusion status in CD31+ Alexa Fluor
647–labeled tumor vasculature was imaged as early as 5 minutes after injection. The FOV in the images is 800 μm × 800 μm. Images
were acquired at a depth of approximately 100 μm in the tumor.
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